WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced ...

WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet ...

Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization ...

Gynecological cancers with amplifications in the CCNE1 gene, which encodes cyclin E1, usually exhibit resistance to standard therapies. Since cyclin-dependent kinase 2 (CDK2) is the primary partner of ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted ...

Among the 10 patients with CCNE1-amplified high grade serous ovarian cancer treated with INX-315, 20% achieved a partial response and 80% achieved stable disease. The Food and Drug Administration (FDA ...

Recent Cedilla Therapeutics Inc. patents describe new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer’s disease, hepatic ...

This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use These findings are notable because several CDK2 inhibitor ...

The mitogen-activated protein kinase (MAPK) pathway integrates growth factor signaling through extracellular signal-regulated kinase (ERK) to control cell proliferation. To study ERK dynamics, many ...

Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that data from its Phase ...